These inhibitors mimic genetic WRN loss, induce DNA damage, and selectively suppress MSI cancer cell model growth, including in patient-derived organoids, tumour xenografts, and PDX models of immunotherapy-resistant disease. Here, WRN is linked to neoplasm.